Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Thomas Yang Sun"'
Autor:
Thomas Yang Sun, MD, MHS, Brandon Nguyen, BA, Simon B. Chen, MD, Yasodha Natkunam, MD, PhD, Sukhmani Padda, MD, Matt van de Rijn, MD, Robert West, MD, PhD, Joel W. Neal, MD, PhD, Heather Wakelee, MD, Jonathan W. Riess, MD, MS
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100498- (2023)
Introduction: CD47 is a tumor antigen that inhibits phagocytosis leading to immune evasion. Anti-CD47 therapy is a promising new immunotherapy across numerous tumor types, but it has not been tested in thymic epithelial tumors (TETs): thymomas and th
Externí odkaz:
https://doaj.org/article/30e41af60d4241beac6dc7f512ddccc4
Autor:
Thomas Yang Sun, Lan Zhao, Paul Van Hummelen, Brock Martin, Kathleen Hornbacker, HoJoon Lee, Li C Xia, Sukhmani K Padda, Hanlee P Ji, Pamela Kunz
Publikováno v:
Endocr Relat Cancer
High-grade (grade 3) neuroendocrine neoplasms (G3 NENs) have poor survival outcomes. From a clinical standpoint, G3 NENs are usually grouped regardless of primary site and treated similarly. Little is known regarding the underlying genomics of these
Autor:
Sai-Hong Ignatius Ou, Pasi A. Jänne, Takashi Seto, Yanfei Gao, Qinying Zhao, Frank Fan, Meijing Li, Chenhui Deng, Kenji Nakamaru, Takeshi Isoyama, Masaya Tachibana, Hiroyuki Hanzawa, Naoki Nakao, Giorgio Senaldi, Alexa B. Schrock, Russell Madison, Heather A. Wakelee, Thomas Yang Sun, Viola W. Zhu, Yuki Shimizu, Ryohei Katayama, Alice T. Shaw, Erkut Borazanci, Kyriakos P. Papadopoulos
Purpose:Taletrectinib (DS-6051b/AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against ROS1 G2032R solvent-front mutation among others. We report the first-in-human U.S. phase I results of taletrectini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c0fc1994ca625c18ce962fd334f7b3a
https://doi.org/10.1158/1078-0432.c.6529236.v1
https://doi.org/10.1158/1078-0432.c.6529236.v1
Autor:
Sai-Hong Ignatius Ou, Pasi A. Jänne, Takashi Seto, Yanfei Gao, Qinying Zhao, Frank Fan, Meijing Li, Chenhui Deng, Kenji Nakamaru, Takeshi Isoyama, Masaya Tachibana, Hiroyuki Hanzawa, Naoki Nakao, Giorgio Senaldi, Alexa B. Schrock, Russell Madison, Heather A. Wakelee, Thomas Yang Sun, Viola W. Zhu, Yuki Shimizu, Ryohei Katayama, Alice T. Shaw, Erkut Borazanci, Kyriakos P. Papadopoulos
Supplemental tables and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47373f841d777bd84e2a008fd2ff0bf3
https://doi.org/10.1158/1078-0432.22475964.v1
https://doi.org/10.1158/1078-0432.22475964.v1
Publikováno v:
Current Oncology Reports. 24:819-824
Lung neuroendocrine tumors (NETs)-typical carcinoids and atypical carcinoids-have unique molecular alterations that are distinct from neuroendocrine carcinomas of the lung and non-small cell lung cancers. Here, we review the role of molecular profili
Autor:
Pamela L. Kunz, Danielle S. Pancirer, Sukhmani K. Padda, Natalie S. Lui, Grace Hwang, Rishi Raj, Kathleen Hornbacker, Alberto Codima, Thomas Yang Sun
Publikováno v:
The European Respiratory Journal
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is considered a preinvasive lesion that may progress to carcinoid tumour [1]. Histologically, it is marked by a proliferation of neuroendocrine cells that is confined to the basem
Autor:
Thomas Yang Sun, Brandon Nguyen, Simon Chen, Yasodha Natkunam, Sukhmani Kaur Padda, Matt Van De Rijn, Heather A. Wakelee, Jonathan W. Riess
Publikováno v:
Journal of Clinical Oncology. 40:8586-8586
8586 Background: Blockade of CD47, an immunoglobulin overexpressed on solid tumor cells that inhibits macrophage phagocytosis, is a promising anti-cancer immunotherapy which has not yet been explored in thymic epithelial tumors (TETs). TETs, includin
Autor:
Ryohei Katayama, Giorgio Senaldi, Pasi A. Jänne, Yanfei Gao, Kyriakos P. Papadopoulos, Erkut Borazanci, Naoki Nakao, Alexa B. Schrock, Masaya Tachibana, Alice T. Shaw, Thomas Yang Sun, Qinying Zhao, Kenji Nakamaru, Heather A. Wakelee, Chenhui Deng, Yuki Shimizu, Sai-Hong Ignatius Ou, Takeshi Isoyama, Viola W. Zhu, Hiroyuki Hanzawa, Meijing Li, Russell Madison, Takashi Seto, Frank Fan
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(18)
Purpose: Taletrectinib (DS-6051b/AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against ROS1 G2032R solvent-front mutation among others. We report the first-in-human U.S. phase I results of taletrectin
Publikováno v:
Journal of Thoracic Oncology. 14:e111-e113
Publikováno v:
Journal of Thoracic Oncology. 14:e75-e77